ENHPATHY is a multidisciplinary science consortium bringing together a world-leading expertise on enhancer biology, epigenomics, bioinformatics and medical genetics to increase scientific knowledge on the molecular basis of human enhanceropathies and to open new diagniostic and therapeutic avenues for patients. ENHPATHY brings together academic institutions, beneficiaries and partners from the non-academic sector, innovative SMEs focused on technological development, bioinformatics companies, communication and management companies, European organisations along with prestigious cultural institutions. To achieve its main objective, ENHPATHY has set up an innovative, integrated and disease-focused research programme. Mutations within coding genes have traditionally been considered the major genetic cause of human diseases. However, it is becoming increasingly clear that the genetic, structural and/or epigenetic disruption of enhancers and their landscapes represent major etiological factors in numerous human diseases (i.e. enhanceropathies), ranging from rare congenital disorders to common diseases associated with ageing (e.g. cancer, diabetes). Although changes in enhancer activity are predicted to have broad pathological and therapeutic implications, we currently have a limited mechanistic understanding of human enhanceropathies. This reflects, at least partly, our still primitive and partial understanding of the mechanisms whereby enhancers can control gene expression. We hypothesize that enhancers are a diverse group of regulatory sequences that can utilize different mechanisms to control gene expression at the transcriptional and/or post-transcriptional level. Consequently, human enhanceropathies are likely to display an equally diverse molecular basis that, we believe, can only be uncovered using highly multidisciplinary systems biology approaches. Chiefly, elucidating the molecular basis of human enhanceropathies has far reaching clinical applications, especially considering the pandemic proportions that some of these disorders are acquiring in recent years. Therefore, the major goal of the ENHPATHY network is to provide early-stage researchers (ESRs) with a multidisciplinary training in which cutting-edge genomic and genetic engineering approaches are combined with various in vitro and in vivo disease models. Moreover, together with our private partners we aim at translating our molecular findings into new diagnostic and therapeutic strategies. Earlier this year, the ENHPATHY consortium submitted a proposal in the frame of the H2020-MSCA-ITN-2018's call which received a total score of 85% and a positive operational capacity notification. In order to increase the success rate of the resubmitted form of ENHPATHY planned for 2019, funding is requested to address the reviewer’s critics related to the importance and the great multidisciplinarity of its network.